within Pharmacolibrary.Drugs.ATC.S;

model S01XA22
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.9999999999999997e-06,
    adminDuration  = 600,
    adminMass      = 0.125 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01XA22</td></tr><td>route:</td><td>intravitreal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ocriplasmin is a recombinant protease enzyme (plasmin derivative) used for the treatment of symptomatic vitreomacular adhesion. It is administered via intravitreal injection and is approved for clinical use. Its enzymatic action facilitates the breakdown of protein matrix components at the vitreoretinal interface, assisting in the resolution of vitreomacular adhesion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults (both sexes) undergoing intravitreal injection of ocriplasmin for vitreomacular adhesion; no comprehensive, peer-reviewed published compartmental PK studies available; parameter values are estimates based on reported ocular pharmacokinetics and product label data.</p><h4>References</h4><ol><li><p>Stalmans, P, &amp; Girach, A (2013). Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. <i>Investigative ophthalmology &amp; visual science</i> 54(10) 6620–6627. DOI:<a href=\"https://doi.org/10.1167/iovs.13-11811\">10.1167/iovs.13-11811</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23982845/\">https://pubmed.ncbi.nlm.nih.gov/23982845</a></p></li><li><p>Willekens, K, et al., &amp; Stalmans, P (2017). Intravitreally Injected Fluid Dispersion: Importance of Injection Technique. <i>Investigative ophthalmology &amp; visual science</i> 58(3) 1434–1441. DOI:<a href=\"https://doi.org/10.1167/iovs.16-20543\">10.1167/iovs.16-20543</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28264098/\">https://pubmed.ncbi.nlm.nih.gov/28264098</a></p></li><li><p>Goldenberg, DT, et al., &amp; Ruby, AJ (2011). Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. <i>Retina (Philadelphia, Pa.)</i> 31(2) 393–400. DOI:<a href=\"https://doi.org/10.1097/IAE.0b013e3181e586b2\">10.1097/IAE.0b013e3181e586b2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21099453/\">https://pubmed.ncbi.nlm.nih.gov/21099453</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01XA22;
